The sand­box: Park­er In­sti­tute throws its re­search mus­cle be­hind gene ther­a­py tech for de­stroy­ing can­cer cells

John Bea­dle

John Bea­dle and the big re­search team at PsiOxus have thought a lot about in­fil­trat­ing the ranks of can­cer cells, to go in­side cells to cause their self-de­struc­tion with one of the in­dus­try’s lead­ing “un­armed” on­colytc virus pro­grams. But they’re al­so go­ing one big step fur­ther, us­ing their gene ther­a­py tech to pen­e­trate these cells to de­liv­er weapons for their mass de­struc­tion. And they’re lin­ing up some pow­er­house al­lies at the Park­er In­sti­tute for Can­cer Im­munother­a­py to speed the work.

What’s the big idea?

PsiOxus — with 95 most­ly re­search staffers in Ox­ford and Philadel­phia — gained con­sid­er­able at­ten­tion for its sys­temic ap­proach to de­liv­er­ing on­colyt­ic virus­es, in­fect­ing cells that would then burst, at­tract­ing T cells in­to the tu­mor. But there are al­so scores of on­colyt­ic virus­es in the pipeline. In this case they’re work­ing a re­verse strat­e­gy to CAR-T. In­stead of mod­i­fy­ing the T cell to go af­ter can­cer cells, they’re mod­i­fy­ing the can­cer cells to get them to en­gage with T cells — en­gi­neer­ing the can­cer cell to ex­press T cell en­gag­ing lig­ands.

The ques­tion has been what genes should be added to do the best job. And they be­lieve the IV ap­proach — steer­ing clear of in­tra­tu­moral in­jec­tions — should help sim­pli­fy things con­sid­er­ably, up­ping their chances of suc­cess in hit­ting the tar­get.

PsiOxus al­ready gained the sup­port of Bris­tol-My­ers Squibb, which part­nered on the biotech’s NG-348 in a $915 mil­lion deal in late 2016. That drug en­codes two im­munomod­u­la­to­ry MiTe pro­teins in its genome: a hu­man CD80 and an an­ti­body frag­ment spe­cif­ic for the T-cell re­cep­tor CD3 pro­tein, both de­signed to muster T cells to at­tack spe­cif­ic can­cer cells on­ly.

Saman­tha Buck­trout

“They’re such a great group,” says Park­er In­sti­tute Di­rec­tor of Re­search Saman­tha Buck­trout about PsiOxus. “When we go to have dis­cus­sions, it’s a ‘no-idea-is-stu­pid’ zone, but al­so an ego-free zone. They’ve done a lot of rig­or­ous work to move their pipeline for­ward, both pre-clin­i­cal and in the clin­ic, and aren’t afraid to take risks. We see a lot of blue sky in terms of where we can go with them, sci­en­tif­i­cal­ly.”

Those blue skies are what spurred tech mogul Sean Park­er to set up his epony­mous in­sti­tute, or­ga­niz­ing a net­work of more than 300 promi­nent sci­en­tists with fi­nan­cial sup­port and cre­at­ing net­works of ex­perts to as­sist the com­pa­nies they work with to dig deep­er and go be­yond the fron­tiers of com­mer­cial I/O. But they’re al­so goal ori­ent­ed, pur­su­ing what PI­CI chief Jeff Blue­stone calls a “sand­box” strat­e­gy: a con­tained, or­ga­nized ap­proach to their work dri­ven by a set of clear ob­jec­tives.

Ex­tra fund­ing is al­ways good, says Bea­dle, but it’s the peo­ple Park­er brings to the ta­ble that make the big dif­fer­ence.

“The key is their net­work of in­sti­tu­tions and aca­d­e­mics,” notes the CEO, who ex­pects to even­tu­al­ly put to­geth­er an­oth­er round for the biotech be­fore even­tu­al­ly set­ting their sights on an IPO.

The plan at PsiOxus is to move two pro­grams in­to the clin­ic, with an IND com­ing in Q1 of next year. The first is a CD40 ag­o­nist, and the sec­ond will in­clude a pack­age of 4 dif­fer­ent genes cov­er­ing a bis­pe­cif­ic with chemokines to at­tract T cells and an­oth­er to ex­press in­ter­fer­on al­pha to ac­ti­vate den­drit­ic cells.

Tesla and SpaceX founder Elon Musk gestures to the audience after being recognized by President Trump following the successful launch of a Falcon 9 rocket at the Kennedy Space Center. (via Getty Images)

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

Elon Musk has joined the global tech crusade now underway to revolutionize vaccine manufacturing — now aimed at delivering billions of doses of a new mRNA vaccine to fight Covid-19. And he’s cutting right to the front.

In a late-night tweet Wednesday, the Tesla chief announced:

Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.

That’s not a lot to go on. But the tweet comes a year after Tesla’s German division in Grohmann and CureVac filed a patent on a “bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing.” CureVac, in the meantime, has discussed a variety of plans to build microfactories that can speed up the whole process for a global supply chain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

UP­DAT­ED: Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Dan Gold, MEI Pharma CEO

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

Four years after Switzerland’s Helsinn put $25 million of cash on the table for an upfront and near-term milestone to take MEI Pharma’s drug pracinostat into a long-running Phase III trial for acute myeloid leukemia, the partners are walking away from a clinical pileup.

The drug — an HDAC inhibitor — failed to pass muster during a futility analysis, as researchers concluded that pracinostat combined with azacitidine wasn’t going to outperform the control group in the pivotal.

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, different teams at a pair of US-based biotechs and in labs in Japan have labored to piece together a group of cancer drug programs, sharing a single corporate umbrella with research colleagues in Japan. But now their far-flung operations have been knit together into a single unit, creating a pipeline with 10 cancer drug development programs — going from early-stage right into Phase III — and a host of discovery projects managed by a collective staff of some 265 people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

Pos­i­tive Covid-19 vac­cine da­ta? New mouse study? OWS in­clu­sion? Yep, but some­how, the usu­al tid­bits from In­ovio back­fire

You don’t go more than 40 years in biotech without ever getting a product to market unless you can learn the art of writing a promotional press release. And Inovio captures the prize in baiting the hook.

Tuesday morning Inovio, which has been struggling to get its Covid-19 vaccine lined up for mass manufacturing, put out a release that touched on virtually every hot button in pandemic PR.

There was, first and foremost, an interim snapshot of efficacy from their Phase I program for INO-4800.

Jan van de Winkel, Genmab CEO

Seat­tle Ge­net­ics, Gen­mab turn on TV for a high­light reel in cer­vi­cal can­cer — but a ri­val biotech promis­es a bet­ter show

Seattle Genetics $SGEN and their partners at Genmab $GMAB polished up some positive Phase II numbers for their antibody drug conjugate tisotumab vedotin — you can call it TV — for recurrent cervical cancer. And while they mapped out a shortcut to a potential quick approval, the big challenge for this team is being presented by a rival biotech which muscled its way into the spotlight for the same indication a year ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.